"Discovery is our Business." Charles Huggins (Nobel Prize Laureate)

Welcome to the Ben May Department

All were hooded at our Divisional Academic Ceremony where Kay Macleod served as the student-selected Faculty Marshall. Lauren Drake, Marina Sharifi, Erin Mowers, Aparajita Hoskote Chourasia, Michelle Beaton.(L to R)

Five PhDs awarded in the Ben May Department for Cancer Research

Faces of Ben May Dept. of Cancer Research View the Gallery

Faces of BMDCR

Biography of Charles Brenton Huggins

"With blood on the hands I have chance, seated at the desk I have no chance." Charles Brenton Huggins (Nobel Prize Laureate) Click Here for Biography of Dr. Huggins

Biography of Charles Brenton Huggins

Welcome to the Ben May Department for Cancer Research

Our vision is a future where cancer is eliminated by total cure or managed by chronic treatment that enables a high quality of life.

The mission of the Ben May Department is embodied in the motto of our founder, the late Nobel Prize winner Charles Huggins: "Discovery is our Business."  In that spirit of discovery, our researchers are pushing the boundaries of understanding and challenging the assumptions that often impede progress.  We believe the first step toward preventing or curing cancer is basic research on the intricacies of the human body and the molecular, cellular, and genetic events that lead to cancer.  Advances in our fundamental understanding of cancer can then be translated into better methods of prevention and diagnosis.

Latest News and Announcements

Subscribe to Latest News and Announcements

Diabetes Medication May Help Combat Triple-Negative Breast Cancer

Early research finds evidence that diabetes drug along with another medication may help women with virulent cancer.

Triple-negative breast cancers (TNBCs) account for roughly 10 to 15 percent of all breast cancers. They disproportionately affect African American and Hispanic women, young women, and women with mutations on the BRCA1 gene.

Read the full post

Old drugs bring new hope to a cancer that lacks precision therapy

Old drugs bring new hope to a cancer that lacks precision therapy

Medicines for diabetes and porphyria repurposed for triple negative breast cancer

Summary: Two older drugs, designed for other purposes, produced promising results in the treatment of mice with triple negative breast cancer.

Read the full post

The commensal microbiome is associated with anti–PD-1 efficacy in metastatic melanoma patients

Good bacteria help fight cancer

Read the full post

Will High-Tech Skin Put an End to Needle Sticks for Diabetes?

Dr. Xiaoyang Wu led a team that used stem cells and the gene-editing technique CRISPR to create skin cells that emit fluorescent light in a particular pattern as blood glucose levels rise.

Full article here https://www.nbcnews.com/mach/science/will-high-tech-skin-put-end-needle-...

Read the full post

CRISPR Gene Therapy via Skin Grafts Treats Obesity and Diabetes in Mice

Xiaoyang Wu

Genetically engineered skin cells grafted onto mice can treat the animals’ diabetes and obesity, according to new research published August 2, 2017 in Cell Stem Cell.

Read the full post

Thomas F. Gajewski has been named the first AbbVie Foundation Professor of Cancer Immunotherapy in Pathology.

Gajewski’s team members study ways to overcome a tumor’s ability to elude the immune system, with a focus on drugs that help the immune system, especially T cells, gain access to tumor sites. They have discovered genetic clues that correlate with response versus resistance, enabling them to identify new therapies to overcome resistance and expand efficacy. They also discovered that certain components of the gut microbiota—microbes that live in a patient’s digestive tract—could stimulate the immune system to attack tumor cells.

Read the full post

Prof. Thomas Gajewski honored for pioneering cancer research

Outstanding Investigator Award provides $4.2 million grant over seven years

The National Cancer Institute, a branch of the National Institutes of Health, has awarded an Outstanding Investigator Award to Prof. Thomas Gajewski. The award supports scientists who demonstrate remarkable productivity in cancer research and guarantees $600,000 in direct costs per year for seven years.

Read the full post